Contact us

Implementation expectations of eCTD 4.0

In this, the final post the eCTD 4.0 blog post series, we shed light on the expected eCTD 4.0 implementation plans and timelines.


In previous blog posts we tackled the drivers and benefits that fuelled the introduction of eCTD 4.0 and talked about the key concepts behind eCTD 4.0 and their impact on product submission. In this, the final post of this series, we shed light on the expected eCTD 4.0 implementation plans and timelines.

In January 2017, the International Council for Harmonisation (ICH) updated the Step 4 (Adoption of an ICH Harmonised Guideline) eCTD 4.0 Implementation Package for Modules 2 through 5. To align themselves with the ICH changes, both the FDA and EMA have released their updated regional implementation guides and are taking steps to ensure eCTD 4.0 readiness as of 2018.


eCTD 4.0 is coming and the pilot phase is almost here

With eCTD 4.0 Implementation Guides (IG) being published by the ICH, EMA, FDA and PMDO, Health Authorities have continued to take concrete steps towards the implementation of the new standard. Over the next year, most agencies will be taking comments and making updates to their IG’s. The next major milestone for industry will be the eCTD 4.0 pilot phase for the various health authorities. Each agency has its own timeline:



Accepting eCTD 4.0 Pilot

Accepting eCTD 4.0 Submissions

Requiring eCTD 4.0 Submissions


Q3 – Q4 2018

Q3 2019




CP – Q3 2019

MRP/DCP – Q3 2020

Not announced

Health Canada

2018 – 2019



PMDA (Japan)


April 1, 2020

April 2, 2022


Keep in mind, all of these timelines are subject to change based on a number of factors: industry acceptance, challenges encountered during the pilot phase, and technical readiness.


What will you need in an eCTD 4.0 tool?

Within the current guidelines of eCTD v 3.2.2, eCTD submissions can be built using any tools, without considering the lifecycle impacts. Backbones can be viewed in a web browser instead of a software. With eCTD 4.0, sponsors must have dedicated tools specifically designed with eCTD 4.0 in mind. A proper publishing software will automate multiple processes inyour eCTD 4.0 submission process:

  • Creation of UUIDs for submission unit, context of use and documents
  • Populating and linking to OIDs for controlled vocabularies from ICH, health authorities and internal systems.
  • Creating the Transitional Mapping Message to move your submission from eCTD 3.2 to eCTD 4.0

The changes in eCTD 4.0 are concentrated in the creation of the backbone message.


Making the decision to move to eCTD 4.0

The health authority timelines have already laid out a general plan for the move to eCTD 4.0. By next year, most health authorities will be conducting pilots to ensure that no gaps remain in the IGs. Talking to your eCTD tool vendor about their plans to participate in those pilots will give you an understanding of your vendor’s eCTD 4.0 timelines.

Sponsors will also need to make a decision about when they wish to move to eCTD 4.0. Current roadmaps from the agencies put eCTD 4.0 requirements at 4 – 5 years away. Transitioning to eCTD 4.0 before the required date will be dependent on the other business value propositions of eCTD 4.0. Three major value propositions stand out right now:

1.    Two-way communication – If you have a product with large amounts of back and forth communications with the FDA or other agencies that implement two-way communication, you may find eCTD 4.0 an easier way to track and manage that information.

2.    Reduced frequency of specification updates – eCTD 4.0 is intended to be a modular standard. That means that almost every update to the specification can be handled through updates of the various controlled vocabularies. From a sponsor perspective, that means that an update to the specification should not necessarily also entail an update to your eCTD software.

3.    Document re-use – For sponsors who are extensively using Cross Application Referencing, Grouped Submissions and other forms of document re-use, eCTD 4.0 offers easier ways for agencies to track and view these documents. Similarly, if you are already submitting the same document to multiple applications, submitting in eCTD 4.0 may save you more time by eliminating the need for any re-work on those documents.

As we have seen with the FDA transition from DTD 2.01 to DTD 3.3, business needs will be the ultimate driver of any specification transition. It will be critical for sponsors to familiarize themselves with eCTD 4.0 to ensure that they are operating at their maximum efficiency. 


William Gardner-Mims, Senior Consultant at EXTEDO